Neutralizing Antibody Responses against Five SARS-CoV-2 Variants and T Lymphocyte Change after Vaccine Breakthrough Infections from the SARS-CoV-2 Omicron BA.1 Variant in Tianjin, China: A Prospective Study

被引:1
|
作者
Zhang, Ying [1 ]
Qu, Jiang Wen [1 ]
Zheng, Min Na [1 ,2 ]
Ding, Ya Xing [1 ]
Chen, Wei [1 ]
Ye, Shao Dong [3 ]
Li, Xiao Yan [1 ,2 ]
Li, Yan Kun [1 ,2 ]
Liu, Ying [1 ]
Zhu, Di [1 ,2 ]
Jin, Can Rui [4 ]
Wang, Lin [4 ]
Yang, Jin Ye [4 ]
Zhai, Yu [4 ]
Wang, Er Qiang [4 ]
Meng, Xing [4 ]
机构
[1] Tianjin Ctr Dis Control & Prevent, Tianjin 300011, Peoples R China
[2] Tianjin Key Lab Pathogen Microbiol Infect Dis, Tianjin 300011, Peoples R China
[3] Chinese Ctr Dis Control & Prevent, Natl Ctr AIDS STD Control & Prevent, Beijing 102206, Peoples R China
[4] Sinovac Biotech Ltd, Beijing 100085, Peoples R China
关键词
SARS-CoV-2; COVID-19; Omicron BA.1; T cells; Neutralizing antibodies; IMMUNITY;
D O I
10.3967/bes2023.047
中图分类号
X [环境科学、安全科学];
学科分类号
08 ; 0830 ;
摘要
Objective To investigate whether Omicron BA.1 breakthrough infection after receiving the SARS-CoV-2 vaccine could create a strong immunity barrier.Methods Blood samples were collected at two different time points from 124 Omicron BA.1 breakthrough infected patients and 124 controls matched for age, gender, and vaccination profile. Live virus-neutralizing antibodies against five SARS-CoV-2 variants, including WT, Gamma, Beta, Delta, and Omicron BA.1, and T-lymphocyte lymphocyte counts in both groups were measured and statistically analyzed.Results The neutralizing antibody titers against five different variants of SARS-CoV-2 were significantly increased in the vaccinated population infected with the Omicron BA.1 variant at 3 months after infection, but mainly increased the antibody level against the WT strain, and the antibody against the Omicron strain was the lowest. The neutralizing antibody level decreased rapidly 6 months after infection. The T-lymphocyte cell counts of patients with mild and moderate disease recovered at 3 months and completely returned to the normal state at 6 months.Conclusion Omicron BA.1 breakthrough infection mainly evoked humoral immune memory in the original strain after vaccination and hardly produced neutralizing antibodies specific to Omicron BA.1. Neutralizing antibodies against the different strains declined rapidly and showed features similar to those of influenza. Thus, T-lymphocytes may play an important role in recovery.
引用
收藏
页码:614 / 624
页数:11
相关论文
共 50 条
  • [41] Serum neutralizing capacity and T-cell response against the omicron BA.1 variant in seropositive children and their parents one year after SARS-CoV-2 infection
    Seidel, Alina
    Jacobsen, Eva-Maria
    Fabricius, Dorit
    Class, Magdalena
    Zernickel, Maria
    Blum, Carmen
    Conzelmann, Carina
    Weil, Tatjana
    Gross, Ruediger
    Bode, Sebastian F. N.
    Renk, Hanna
    Elling, Roland
    Stich, Maximillian
    Kirchhoff, Frank
    Debatin, Klaus-Michael
    Muench, Jan
    Janda, Ales
    FRONTIERS IN PEDIATRICS, 2023, 11
  • [42] Cross-Neutralizing Breadth and Longevity Against SARS-CoV-2 Variants After Infections
    Kurahashi, Yukiya
    Sutandhio, Silvia
    Furukawa, Koichi
    Tjan, Lidya Handayani
    Iwata, Sachiyo
    Sano, Shigeru
    Tohma, Yoshiki
    Ohkita, Hiroyuki
    Nakamura, Sachiko
    Nishimura, Mitsuhiro
    Arii, Jun
    Kiriu, Tatsunori
    Yamamoto, Masatsugu
    Nagano, Tatsuya
    Nishimura, Yoshihiro
    Mori, Yasuko
    FRONTIERS IN IMMUNOLOGY, 2022, 13
  • [43] A booster dose of Delta × Omicron hybrid mRNA vaccine produced broadly neutralizing antibody against Omicron and other SARS-CoV-2 variants
    I-Jung Lee
    Cheng-Pu Sun
    Ping-Yi Wu
    Yu-Hua Lan
    I-Hsuan Wang
    Wen-Chun Liu
    Joyce Pei-Yi Yuan
    Yu-Wei Chang
    Sheng-Che Tseng
    Szu-I Tsung
    Yu-Chi Chou
    Monika Kumari
    Yin-Shiou Lin
    Hui-Feng Chen
    Tsung-Yen Chen
    Chih-Chao Lin
    Chi-Wen Chiu
    Chung-Hsuan Hsieh
    Cheng-Ying Chuang
    Chao-Min Cheng
    Hsiu-Ting Lin
    Wan-Yu Chen
    Fu-Fei Hsu
    Ming-Hsiang Hong
    Chun-Che Liao
    Chih-Shin Chang
    Jian-Jong Liang
    Hsiu-Hua Ma
    Ming-Tsai Chiang
    Hsin-Ni Liao
    Hui-Ying Ko
    Liang-Yu Chen
    Yi-An Ko
    Pei-Yu Yu
    Tzu-Jing Yang
    Po-Cheng Chiang
    Shang-Te Hsu
    Yi-Ling Lin
    Chong-Chou Lee
    Han-Chung Wu
    Mi-Hua Tao
    Journal of Biomedical Science, 29
  • [44] A community study of neutralizing antibodies against SARS-CoV-2 in China
    Lv, Yitong
    Huang, Lei
    Wang, Junhu
    He, Hui
    Song, Libo
    He, Jia
    Xu, Lida
    Yu, Changyuan
    Mei, Ying
    Gao, Qi
    FRONTIERS IN IMMUNOLOGY, 2023, 14
  • [45] Antibody responses against SARS-CoV-2 variants induced by four different SARS-CoV-2 vaccines in health care workers in the Netherlands: A prospective cohort study
    van Gils, Marit J.
    Lavell, Ayesha
    van der Straten, Karlijn
    Appelman, Brent
    Bontjer, Ilja
    Poniman, Meliawati
    Burger, Judith A.
    Oomen, Melissa
    Bouhuijs, Joey H.
    van Vught, Lonneke A.
    Slim, Marleen A.
    Schinkel, Michiel
    Wynberg, Elke
    van Willigen, Hugo D. G.
    Grobben, Marloes
    Tejjani, Khadija
    van Rijswijk, Jacqueline
    Snitselaar, Jonne L.
    Caniels, Tom G.
    Vlaar, Alexander P. J.
    Prins, Maria
    de Jong, Menno D.
    de Bree, Godelieve J.
    Sikkens, Jonne J.
    Bomers, Marije K.
    Sanders, Rogier W.
    PLOS MEDICINE, 2022, 19 (05)
  • [46] Poor neutralizing antibody responses in 106 patients with WM after vaccination against SARS-CoV-2: a prospective study
    Gavriatopoulou, Maria
    Terpos, Evangelos
    Ntanasis-Stathopoulos, Ioannis
    Briasoulis, Alexandros
    Gumeni, Sentiljana
    Malandrakis, Panagiotis
    Fotiou, Despina
    Migkou, Magdalini
    Theodorakakou, Foteini
    Eleutherakis-Papaiakovou, Evangelos
    Kanellias, Nikolaos
    Kastritis, Efstathios
    Trougakos, Ioannis P.
    Dimopoulos, Meletios A.
    BLOOD ADVANCES, 2021, 5 (21) : 4398 - 4405
  • [47] Cumulative incidence of SARS-CoV-2 infection in the general population of the Valencian Community (Spain) after the surge of the Omicron BA.1 variant
    Camacho, Jorge
    Gimenez, Estela
    Albert, Eliseo
    Zulaica, Joao
    Alvarez-Rodriguez, Beatriz
    Torres, Ignacio
    Rusu, Luciana
    Burgos, Javier S.
    Peiro, Salvador
    Vanaclocha, Hermelinda
    Limon, Ramon
    Jesus Alcaraz, Maria
    Sanchez-Paya, Jose
    Diez-Domingo, Javier
    Comas, Inaki
    Gonzales-Candelas, Fernando
    Geller, Ron
    Navarro, David
    JOURNAL OF MEDICAL VIROLOGY, 2023, 95 (01)
  • [48] Clinical utility of quantitative immunoassays and surrogate virus neutralization tests for predicting neutralizing activity against the SARS-CoV-2 Omicron BA.1 and BA.5 variants
    Lee, Beomki
    Ko, Jae-Hoon
    Kim, Yong Chan
    Baek, Jin Yang
    Park, Yoon Soo
    Song, Kyoung-Ho
    Kim, Eu Suk
    Lee, Kyoung Hwa
    Song, Young Goo
    Ahn, Jin Young
    Choi, Jun Yong
    Choi, Won Suk
    Bae, Seongman
    Kim, Sung-Han
    Jeong, Hye Won
    Lee, Young Jae
    Kim, Hye-Jin
    Choi, Ju-Yeon
    Kim, Byoungguk
    Kim, Shin-Woo
    Kwon, Ki Tae
    Peck, Kyong Ran
    Kang, Eun-Suk
    JOURNAL OF MEDICAL VIROLOGY, 2023, 95 (12)
  • [49] Reduced neutralization against Delta, Gamma, Mu, and Omicron BA.1 variants of SARS-CoV-2 from previous non-Omicron infection
    Paola Pidal
    Jorge Fernández
    Constanza Airola
    Miguel Araujo
    Ana María Menjiba
    Héctor San Martín
    Nicole Bruneau
    Monserrat Balanda
    Coral Elgueta
    Rodrigo Fasce
    María Teresa Valenzuela
    Ariel Orellana
    Eugenio Ramírez
    Medical Microbiology and Immunology, 2023, 212 : 25 - 34
  • [50] Therapeutic Potential of Neutralizing Monoclonal Antibodies (nMAbs) against SARS-CoV-2 Omicron Variant
    Parua, Pijus
    Ghosh, Somnath
    Jana, Koushik
    Seth, Arnab
    Debnath, Biplab
    Rout, Saroj Kumar
    Sarangi, Manoj Kumar
    Dash, Rasmita
    Halder, Jitu
    Rajwar, Tushar Kanti
    Pradhan, Deepak
    Rai, Vineet Kumar
    Dash, Priyanka
    Das, Chandan
    Kar, Biswakanth
    Ghosh, Goutam
    Rath, Goutam
    CURRENT PHARMACEUTICAL DESIGN, 2025, 31 (10) : 753 - 773